Clinical Trials Logo
  1. Home
  2. Phobic Disorders
  3. NCT02432703

A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder

Phobic Disorders Clinical Trial

Official title:
A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects With Social Anxiety Disorder.

Clinical Trial Summary

The purpose of this study is to investigate the efficacy of JNJ-42165279 during 12 weeks of treatment in participants with Social Anxiety Disorder (SAD).

Clinical Trial Description

This is a Phase 2a randomized (study drug assigned by chance), double-blind (neither the Investigator nor the participants know about the study intervention), placebo-controlled, parallel-group, multi-center study of JNJ-42165279 in participants with social anxiety disorder. Participants will receive 25 milligram (mg) JNJ-42165279 or matching placebo orally once-daily from Day 1 up to 12 weeks. Participants will primarily be assessed for the change from baseline in Liebowitz Social Anxiety Scale (LSAS) at Week 12. Safety will be monitored throughout the study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02432703
Study type Interventional
Source Janssen Research & Development, LLC
Contact
Status Completed
Phase Phase 2
Start date June 11, 2015
Completion date August 9, 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT01963806 - ACT-smart: Smartphone-supplemented iCBT for Social Phobia and/or Panic Disorder N/A
Completed NCT00121069 - Study of Escitalopram in the Treatment of Specific Phobia Phase 2/Phase 3
Recruiting NCT03653923 - Neurophysiological Correlates of Exposition Therapy in Spider Phobia N/A
Completed NCT00184106 - RCT of Cognitive Therapy, Paroxetine, Combined CT and Paroxetine and Placebo Phase 4
Completed NCT00051220 - Treatment for Specific Phobias in Children Phase 1/Phase 2
Completed NCT02387047 - Validity of a Self-administered Questionnaire to Screen Phobia of Falling in the Elderly N/A
Completed NCT02310152 - Explanatory Clinical Trial of a Novel Parent Intervention for Childhood Anxiety (SPACE) N/A
Completed NCT00000370 - Treatment of Social Phobia N/A
Completed NCT03012035 - The Role of Treatment Expectation in Exposure Training With Spider Fearful Participants N/A
Completed NCT02007694 - Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants Phase 2/Phase 3
Active, not recruiting NCT03188575 - Effectiveness & Cost-effectiveness of Internet-delivered Interventions for Depression and Anxiety Disorders in IAPT N/A
Terminated NCT01574014 - Glucocorticoid Treatment for Social Phobia Phase 2
Completed NCT00734422 - Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants Phase 2/Phase 3
Not yet recruiting NCT02336802 - Threat-Avoidance Learning in Anxiety Patients N/A
Completed NCT01361074 - In Vivo Versus Augmented Reality Exposure for Small Animal Phobia N/A
Completed NCT00104195 - A Research Study of How Teens With and Without an Anxiety Disorder Make Decisions Phase 1
Completed NCT00035412 - St. John's Wort Versus Placebo in Social Phobia Phase 2
Completed NCT00128401 - Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia Phase 2
Recruiting NCT02020824 - Virtual Reality and Concept of Control in the Treatment of Acrophobia N/A
Terminated NCT01623583 - Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias Phase 4